Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005 Jul. 62(7):1057-62. [QxMD MEDLINE Link].
Ando Y, Suhr OB. Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP). Amyloid. 1998 Dec. 5(4):288-300. [QxMD MEDLINE Link].
Plante-Bordeneuve V, Lalu T, Misrahi M, et al. Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. Neurology. 1998 Sep. 51(3):708-14. [QxMD MEDLINE Link].
Hagiwara K, Ochi H, Suzuki S, et al. Highly selective leptomeningeal amyloidosis with transthyretin variant Ala25Thr. Neurology. April 2009. 72:1358-60. [QxMD MEDLINE Link].
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease. Pfizer Press Release. 06 May 2019. Available at https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_vyndaqel_and_vyndamax_for_use_in_patients_with_transthyretin_amyloid_cardiomyopathy_a_rare_and_fatal_disease.
Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003 Sep. 10(3):160-84. [QxMD MEDLINE Link].
Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008. 40 (3):232-9. [QxMD MEDLINE Link].
Zhen DB, Swiecicki PL, Zeldenrust SR, Dispenzieri A, Mauermann ML, Gertz MA. Frequencies and geographic distributions of genetic mutations in transthyretin- and non-transthyretin-related familial amyloidosis. Clin Genet. 2015 Oct. 88 (4):396-400. [QxMD MEDLINE Link].
Bulawa C, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. PNAS. June 12, 2012. 109:9629-9634. [QxMD MEDLINE Link].
Suhr OB, Svendsen IH, Andersson R, Danielsson A, Holmgren G, Ranløv PJ. Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med. 2003 Sep. 254(3):225-35. [QxMD MEDLINE Link].
Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997 Feb 13. 336(7):466-73. [QxMD MEDLINE Link].
Saraiva MJ, Birken S, Costa PP. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest. 1984 Jul. 74(1):104-19. [QxMD MEDLINE Link].
Jacobson DR, Buxbaum JN. Genetic aspects of amyloidosis. Adv Hum Genet. 1991. 20:69-123, 309-11. [QxMD MEDLINE Link].
Benson MD. The hereditary amyloidoses. Best Pract Res Clin Rheumatol. December 2003. Volume 17, Issue 6:909–927. [QxMD MEDLINE Link]. [Full Text].
Rapezzi C, Riva L, Quarta CC, Perugini E, Salvi F, Longhi S. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid. 2008 Mar. 15(1):40-8. [QxMD MEDLINE Link].
Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain. 2000 Jul. 123 (Pt 7):1495-504. [QxMD MEDLINE Link].
Ruberg FL, Berk JL. Transthyretin (TTR) Cardiac Amyloidosis. Circulation. 04 Sept 2012. 126:1286-1300. [QxMD MEDLINE Link]. [Full Text].
Wange N, Anan I, Ericzon BG, Pennlert J, Pilebro B, Suhr OB, et al. Atrial Fibrillation and Central Nervous Complications in Liver Transplanted Hereditary Transthyretin Amyloidosis Patients. Transplantation. 2018 Feb. 102(2):e59-e66. [QxMD MEDLINE Link]. [Full Text].
Phull P, Sanchorawala V, Connors LH, Doros G, Ruberg FL, Berk JL, et al. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid. 2018 Mar. 25(1):62-67. [QxMD MEDLINE Link]. [Full Text].
Rapezzi C, Perugini E, Salvi F, Grigioni F, Riva L, Cooke RM, et al. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies?. Amyloid. 2006 Sep. 13(3):143-53. [QxMD MEDLINE Link].
Parman Y, Adams D, Obici L, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016. 29 (suppl 1):S000–S000. [QxMD MEDLINE Link].
Adams D, Suhr OB, Hund E, Obici L, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016. 29 (suppl1):S000-S000. [QxMD MEDLINE Link].
Vergaro G, Solal AC, Emdin M. Wild Type Transthyretin Amyloidosis: Don't Miss Diagnosis!. Int J Cardiol. 01 Aug 2020. 312:96-97. [QxMD MEDLINE Link]. [Full Text].
Simmons Z, Specht, C. The Neuromuscular Manifestations of Amyloidosis. Journal of Clin Neuromuscular Dis. March 2010. 11:145-157. [QxMD MEDLINE Link].
Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. J Am Coll Cardiol. 2015. 66:2451-66. [QxMD MEDLINE Link].
Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2020 Jan 6. [QxMD MEDLINE Link].
[Guideline] Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet Journal of Rare Diseases. 2013. v.8, 31:[QxMD MEDLINE Link]. [Full Text].
Wiklund R, Kadkhodaee A, Andersson K, et al. Normal scores of deep breathing tests: beware of dysrhythmia in transthyretin amyloidosis. Amyloid: The Journal of Protein Folding Disorders. 25 Jan 2018. 54-61. [Full Text].
Klaassen SHC, Tromp J, Nienhuis HLA, van der Meer P, van den Berg MP, Blokzijl H, et al. Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. Am J Cardiol. 2018 Jan 1. 121(1):107-112. [QxMD MEDLINE Link]. [Full Text].
Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol. 2015 Feb. 12 (2):91-102. [QxMD MEDLINE Link].
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. June 14, 2016. Volume 133, Issue 24:2404-2412. [QxMD MEDLINE Link]. [Full Text].
Wisniowski B, Wechalekar A. Confirming the Diagnosis of Amyloidosis. Acta Haematol. 16 Jan 2020. 1-10. [QxMD MEDLINE Link]. [Full Text].
Treglia G, Glaudemans AWJM, Bertagna F, Hazenberg BPC, Erba PA, Giubbini R, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging. 2018 Oct. 45(11):1945-1955. [QxMD MEDLINE Link]. [Full Text].
Rapezzi C, Merlini G, Quarta, C, et al. Systemic Cardiac Amyloidosis: Disease Profiles and Clnical Courses of the 3 Main Types. Circulation. Sep 2009. 120:1203-1212. [QxMD MEDLINE Link].
Montagna P, Marchello L, Plasmati R, et al. Electromyographic findings in transthyretin (TTR)-related familial amyloid polyneuropathy (FAP). Electroencephalogr Clin Neurophysiol. 1996 Oct. 101(5):423-30. [QxMD MEDLINE Link].
Planté-Bordeneuve V, Ferreira A, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy. Neurology. Aug 2007. 69:693-698. [QxMD MEDLINE Link].
Inês M, Coelho T, Conceição I, Ferreira L, de Carvalho M, Costa J. Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study. Orphanet J Rare Dis. 2020 Mar 6. 15 (1):67. [QxMD MEDLINE Link]. [Full Text].
Ueda M, Sekijima Y, Koike H, Yamashita T, Yoshinaga T, Ishii T, et al. Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. J Neurol Sci. 2020 Apr 2. 414:116813. [QxMD MEDLINE Link].
Hawkins, P. N., Ando, Y., Dispenzeri, A., et al. Evolving landscape in the management of transthyretin amyloidosis. Annals of Medicine. 2015 Nov 17. 47(8):625–638. [QxMD MEDLINE Link]. [Full Text].
Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5. 379 (1):11-21. [QxMD MEDLINE Link].
Merlini G, Coelho T, Waddington Cruz M, Li H, Stewart M, Ebede B. Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years. Neurol Ther. 2020 Feb 27. [QxMD MEDLINE Link].
Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK1, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;. 379(1):22-31. [QxMD MEDLINE Link]. [Full Text].
Brannagan TH 3rd, et al; NEURO-TTR Open-Label Extension Investigators. Early Data on Long-Term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis: A 2-Year Update From the Open-Label Extension of the NEURO-TTR Trial. Eur J Neurol. 2020 Apr 28. [QxMD MEDLINE Link].
FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis. U.S. Food & Drug Administration. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatments-heart-disease-caused-serious-rare-disease-transthyretin-mediated#:~:text=On%20May%203%2C%20the%20U.S.,approved%20treatments%20for%20ATTR%2DCM.. May 6, 2019; Accessed: July 23, 2020.
Cruz MW, Benson MD. A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis. Neurol Ther. 2015. 4:61-79. [QxMD MEDLINE Link].
Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long- term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 05 Aug 2016. Vol. 23 , Iss. 3:178-183. [QxMD MEDLINE Link]. [Full Text].
Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 13 Sept 2018. 379:1007-1016. [Full Text].
Suhr OB, Larsson M, Ericzon B-G, Wilczek HE. Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry. Transplantation. 2015. 00:1-9. [QxMD MEDLINE Link].
Adams D, Tournev IL, Taylor MS, Coelho T, Pante-bordeneuve V, Berk JL, et al. HELIOS-A: 9-month results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (1234). Presented at the April 19, 2021 at the American Academy of Neurology 2021 Annual Meeting. Neurology. 2021 Apr 13. 96(15 suppl):[Full Text].
Amvuttra (vutrisiran) [package insert]. Cambridge, MA: Alnylam Pharmaceuticals. 2022 Jun. Available at [Full Text].
Sant’Anna, R., Gallego, P., Robinson, L. Z., et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nature Communications. 2016 Feb 23. 7:[QxMD MEDLINE Link]. [Full Text].
Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013 Dec 25. 310(24):2658-67. [QxMD MEDLINE Link].
Anderson P. NSAID halts progression in familial amyloid polyneuropathy. December 30, 2013. Medscape Medical News. Available at http://www.medscape.com/viewarticle/818483. Accessed: January 10, 2017.
The Familial Amyloidotic Polyneuropathy World Transplant Registry. Available at http://www.fapwtr.org. April 24, 2018; Accessed: May 1, 2020.
Ericzon B-G, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?. Transplantation. 2015. 99:1847-1854. [QxMD MEDLINE Link].
Beirao JM, Maleiro J, Lemos C, Beirao I, Costa P, Torres P. Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases. Amyloid. 2015. 22:117-122. [QxMD MEDLINE Link].
aus dem Siepen F, Bauer R, Aurich M, Buss SJ, Steen H, Altland K, et al. Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Design, Development and Therapy. 2015 Dec 4. v9:6319–6325. [QxMD MEDLINE Link]. [Full Text].
Desai HV, Aronow WS, Peterson SJ, et al. Cardiac Amyloidosis: Approaches to Diagnosis and Management. Cardiology in Review. Jan 2010. 18:1-11. [QxMD MEDLINE Link].
Berk JL, Barroso FA, Coelho A. Oligonucleotide Drugs for Transthyretin Amyloidosis. N Engl J Med. 2018 Nov 22. 379:2085-2086. [QxMD MEDLINE Link]. [Full Text].
Ericzon BG, Larsson M, Herlenius G, Wilczek HE. Report from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR) and the Domino Liver Transplant Registry (DLTR). Amyloid. 2003 Aug. 10 Suppl 1:67-76. [QxMD MEDLINE Link].
Damas AM, Saraiva MJ. Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies. J Struct Biol. 2000 Jun. 130(2-3):290-9. [QxMD MEDLINE Link].
Monteiro E, Freire A, Barroso E. Familial amyloid polyneuropathy and liver transplantation. J Hepatol. 2004 Aug. 41(2):188-94. [QxMD MEDLINE Link].
Lauro A, Diago Usò T, Masetti M, Di Benedetto F, Cautero N, De Ruvo N, et al. Liver transplantation for familial amyloid polyneuropathy non-VAL30MET variants: are cardiac complications influenced by prophylactic pacing and immunosuppressive weaning?. Transplant Proc. 2005 Jun. 37(5):2214-20. [QxMD MEDLINE Link].
Klabunde T, Petrassi HM, Oza VB, et al. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol. 2000 Apr. 7(4):312-21. [QxMD MEDLINE Link].
Tojo K, Sekijima Y, Kelly JW, et al. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res. 2006. 56:441-449. [QxMD MEDLINE Link].
Palha JA, Ballinari D, Amboldi N, Cardoso I, Fernandes R, Bellotti V, et al. 4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. Am J Pathol. 2000 Jun. 156(6):1919-25. [QxMD MEDLINE Link].
Peterson SA, Klabunde T, Lashuel HA, et al. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci U S A. 1998 Oct 27. 95(22):12956-60. [QxMD MEDLINE Link].
Saraiva MJ. Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett. 2001 Jun 8. 498(2-3):201-3. [QxMD MEDLINE Link].
Suhr OB, Herlenius G, Friman S. Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl. 2000 May. 6(3):263-76. [QxMD MEDLINE Link].